

Applicants : Alexander Gad et al.  
U.S. Serial No.: 09/816,989  
Filed : March 23, 2001  
Page : 2

Page 1, paragraph 1:

The present application claims the benefit of U.S. Provisional Application No. 60/101,825, filed September 25, 1998, and U.S. Provisional Application No. 60/101,693, filed September 25, 1998, which are incorporated by reference herein.

Page 14, Table 1

Table 1. Selected TV-markers amino acid sequences

TV-#	SEQ ID NO	Sequence
TV-35	1	AKKYAKKEKAACKKAYKKEAKAKAAEAAAKEYAAAYEA
TV-45	2	AKKYAKKAKAECAKKAKYKAAEAKKAKEYEKAEEAKAAKE-AAYEA
TV-56	3	AKKYAKKEKAYAKKAECKAACKKAEAKAYKAAEAKKKAEAKY-KAEAAKAAKEAAYEA
TV-66	4	AKKYAKKEKAYAKKAKAEAKKAACKKAKAEAKKYAKAAKAEC-KEYAAAKEYKAEEAKAAKEAAYEA
TV-77	5	AKKYAKKEKAYAKKAECKAACKKAEAKAYKAAEAKKKAKAEAKKYAKKAECKEYAAAKEYKAEEAKAAKEAAYEA
TV-86	6	AKKYAKKEKAYAKKAECKAACKKAEAKAYKAAEAKKKAKAEAKKYAKKAECKEYAAAKEYKAEEAKKAKYKAEEAKAAKEAAYEA
TV-109	7	AKKYAKKAECKAYAKKAACKKAKYKKEAKKAYKAAEAKK-KAKAEAKKYAKEAACKKAKYKAEAKKYAKAAKAECKEYA-AAEAKKAECKEYKAEEAKAAKEAAYEA

Applicants : Alexander Gad et al.  
Serial No. : 09/816,989  
Filed : March 23, 2001  
Page 3

Page 56, paragraphs 1-2:

The present invention provides molecular weight markers for accurate determination of the molecular weight of glatiramer acetate and other copolymers. The present invention further provides a plurality of molecular weight markers for determining the molecular weight of glatiramer acetate and other copolymers which display linear relationships between molar ellipticity and molecular weight, and between retention time and the log of the molecular weight. The molecular weight markers also optimally demonstrate biological activity similar to glatiramer acetate or corresponding copolymers and can be used for treating or preventing various immune diseases. In addition, the subject invention provides pharmaceutical compositions for the treatment of immune diseases comprising a polypeptide having an identified molecular weight and an amino acid composition corresponding to glatiramer acetate or a terpolymer.

In the Claims

Please cancel claims 20, 34-35, 47-49, 70-91 and 94-122 without prejudice to applicants rights to pursue the subject matter of these claims in this or a related application. In addition, please add new claims 123-143 as follows:

123. (New) A method of treating or preventing an autoimmune disease in a mammal comprising administering to the mammal a purified polypeptide having the amino acid sequence set forth in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:7, or a mixture of the purified polypeptides.

124. (New) The method of claim 123 wherein the purified polypeptide